Mesenchymal Stem Cells as a Biological Drug for Heart Disease: Where Are We With Cardiac Cell-Based Therapy?
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 26185208.
- Also identified by DOI 10.1161/CIRCRESAHA.117.306306 and PMC identifier 4571454.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cell-based treatment represents a new generation in the evolution of biological therapeutics. A prototypic cell-based therapy, the mesenchymal stem cell, has successfully entered phase III pivotal trials for heart failure, signifying adequate enabling safety and efficacy data from phase I and II trials. Successful phase III trials can lead to approval of a new biological therapy for regenerative medicine.
Medical subject headings
- Heart Failure
- Mesenchymal Stem Cell Transplantation
- Myocardial Infarction
- Regenerative Medicine